The Cachexia drugs in development market research report provides comprehensive information on the therapeutics under development for Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cachexia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cachexia and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Cachexia by 20 companies/universities/institutes. The top development phase for Cachexia is preclinical with 13 drugs in that stage. The Cachexia pipeline has 21 drugs in development by companies and three by universities/ institutes. Some of the companies in the Cachexia pipeline products market are: Novo Nordisk, Epitracker and Aventi.
The key targets in the Cachexia pipeline products market include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), and Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM).
The key mechanisms of action in the Cachexia pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with four drugs in Preclinical. The Cachexia pipeline products include five routes of administration with the top ROA being Oral and nine key molecule types in the Cachexia pipeline products market including Small Molecule, and Fusion Protein.
Cachexia overview
Cachexia, also known as wasting syndrome, is characterized by loss of skeletal muscle mass. Symptoms include involuntary unintentional weight loss, skeletal muscle wasting, and anorexia. Risk factors include HIV, cancer, chronic obstructive pulmonary disease, congestive heart failure, rheumatoid arthritis, and cystic fibrosis. Treatment includes appetite stimulants, exercise, and dietary supplements.
For a complete picture of Cachexia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
